Results 291 to 300 of about 1,006,148 (403)

Atypical Wounds in Chronic Graft‐Versus‐Host Disease and Peripheral Arterial Disease Caused by Tyrosine Kinase Inhibitors

JEADV Clinical Practice, EarlyView.
ABSTRACT The term “atypical wounds” primarily refers to lesions with immunological or cancerous etiologies. However, these wounds can also be drug‐induced. We report about a 32‐year‐old man with a 6‐year history of chronic myelogenous leukemia (CML) and chronic graft‐versus‐host disease (cGvHD) following an HLA‐compatible allogeneic stem cell ...
E. K. Stuermer, K. Malik, C. Willers, M. Augustin   +3 more
wiley   +1 more source

BCOR mutations define a therapeutic vulnerability to DHODH Inhibition in acute myeloid leukemia. [PDF]

Ann Hematol
Robert F, Badja C, Boushaki S, Degasperi A, Memari Y, Momen S, Roumeliotis TI, Kozik Z, Gozdecka M, Choudhary J, Vassiliou G, Koh GC, Nik-Zainal S.   +12 more
europepmc   +1 more source

Supplementary Table 15 from Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia

William M. Yashar, Brittany M. Curtiss, Daniel J. Coleman, Jake VanCampen, Garth Kong, Jommel Macaraeg, Joseph Estabrook, Emek Demir, Nicola Long, Daniel Bottomly, Shannon K. McWeeney, Jeffrey Tyner, Brian Druker, Julia E. Maxson, Theodore P. Braun   +14 more
openalex   +1 more source

[Clinical observation of 12 patients with refractory/relapsed acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation containing cladribine regimen].

, 2019
Hao Ai, Yuewen Fu, Y Q Wang, Xudong Wei, Yong-Wen Song   +4 more
openalex   +2 more sources

Dupilumab and Systemic Hematologic Malignancies: Case Series and Literature Review

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Atopic dermatitis (AD) is a chronic inflammatory skin disease affecting 15%–20% of children and 3%–10% of adults. An increased risk of systemic lymphomas – but not leukemias – has been reported in patients with AD. Dupilumab, a monoclonal IgG4 antibody targeting IL‐4 and IL‐13 signaling, is approved for moderate‐to‐severe AD and is ...
Nello Tommasino, Cataldo Patruno, Francesca di Vico, Maddalena Napolitano   +3 more
wiley   +1 more source

Precursor Dendritic Cell Proliferation in Multiple Myeloma: A Precursor to Acute Myeloid Leukemia. [PDF]

Hematol Rep
Reberšek K, Anžej Doma S, Škerget M, Podgornik H.   +3 more
europepmc   +1 more source

Bilateral Leukemic Pulmonary Infiltrate: A Rare Manifestation of Acute Myeloid Leukemia

, 2014
Umer
openalex   +2 more sources

Vitexin Attenuates the Growth and Glycolysis of Acute Myeloid Leukemia Cells by Suppressing the HIF‐1α‐Modulated YAP Pathway Under Hypoxic Conditions

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Vitexin, an apigenin flavone glycoside, exhibits antitumor activity against various cancers including leukemia. Hypoxia enhances glycolysis, thereby promoting tumor growth. In this study, we aimed to explore the effects of vitexin on hypoxia‐induced growth and glycolysis in acute myeloid leukemia (AML) cells and determine the underlying ...
Ping Wang, Jia‐Jia Zhang, Fang Zhang, Xiao‐Jie Qu, Hui Zhang   +4 more
wiley   +1 more source

Vascular complications in NPM1-Mutated acute myeloid leukemia: clinical features and prognosis. [PDF]

Ann Hematol
Wang X, Mo W, Chen M, Sui J, Bian R, Yan X.   +5 more
europepmc   +1 more source

Cost-effectiveness of adding quizartinib to induction chemotherapy for patients with FLT3- mutant acute myeloid leukemia [PDF]

Jan Philipp Bewersdorf, Kishan Patel, Rory M. Shallis, Nikolai A. Podoltsev, Tariq Kewan, Jessica M. Stempel, Lourdes Mendez, Maximilian Stahl, Eytan M. Stein, Scott F. Huntington, George Goshua, Amer M. Zeidan   +11 more
openalex   +1 more source